| Basics |
Viking Therapeutics, Inc.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
|
| IPO Date: |
April 29, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.36B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.45 | 3.35%
|
| Avg Daily Range (30 D): |
$1.21 | 3.32%
|
| Avg Daily Range (90 D): |
$0.97 | 3.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.83M |
| Avg Daily Volume (30 D): |
3.69M |
| Avg Daily Volume (90 D): |
5.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
115 |
| Avg Trade Size (Sh.) (30 D): |
77 |
| Avg Trade Size (Sh.) (90 D): |
90 |
| Institutional Trades |
| Total Inst.Trades: |
4,738 |
| Avg Inst. Trade: |
$2.78M |
| Avg Inst. Trade (30 D): |
$2.16M |
| Avg Inst. Trade (90 D): |
$2.21M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.35M |
| Avg Closing Trade (30 D): |
$8.02M |
| Avg Closing Trade (90 D): |
$8.08M |
| Avg Closing Volume: |
249.76K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-2.12
|
$-.81
|
$-.58
|
|
Diluted EPS
|
$-2.12
|
$-.81
|
$-.58
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -237.39M
|
$ -90.79M
|
$ -65.56M
|
|
Operating Income / Loss
|
$ -274.84M
|
$ -98.56M
|
$ -74.57M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 50.12M
|
$ 66.5M
|
$ -4.05M
|
|
PE Ratio
|
|
|
|
|
|
|
